Jump to Main Contents
国立がん研究センター 中央病院

Home > ATLAS Project Research Members

ATLAS Project Research Members

National Cancer Center Hospital (Tokyo, Japan)

YONEMORI Kan (Depertment of Medical Oncology)

YONEMORI Kan

YONEMORI Kan MD, PhD 

Dr. YONEMORI's story

Kan Yomemori, PhD., MD. is the director of Department of Medical Oncology from 2020 and co-staff physician of the department of Experimental Therapeutics (Phase I unit) at the National Cancer Center Hospital, Tokyo, Japan. Dr Kan Yonemori had medical reviewer experience in the Pharmaceuticals and Medical Devices Agency and the visiting researcher in the US National Cancer Institute and the Food and Drug Administration. Dr Kan Yonemori is one of expert medical oncologists for breast cancer, gynecological cancer, germ cell tumor, sarcoma and other miscellaneous rare cancers. Dr Yonemori is one of lead Principle Investigators in the National Cancer Center Hospital, Tokyo and he lead the field of oncology drug development scene including phase I trial to phase II/III trials for various cancers.

Research interests

Medical Oncology, Drug development, Reguraltory science and International collaboration.

Professional Experiences


  • 2021-Present Director, Department of Medical Oncology, National Cancer Center Hospital
  • 2020-2021 Director, Department of Breast and Medical Oncology, National Cancer Center Hospital
  • 2015-2020 Hospital Ward Chief Physician, Department of Breast and Medical Oncology, National Cancer Center Hospital2013-2015 Chief
  • Physician, Department of Breast and Medical Oncology, National Cancer Center Hospital
  • 2010-2013 Staff Physician, Department of Breast and Medical Oncology, National Cancer Center Hospital

Selected publications

  1. Kashima J, Yoshida M, Jimbo K, Izutsu K, Ushiku T, Yonemori  K, Yoshida A. ALK-positive Histiocytosis of the Breast: A Clinicopathologic Study Highlighting Spindle Cell Histology. Am J Surg Pathol. 2021 Mar 1;45(3):347-355.
  2. Ryu S, Ohuchi M, Yagishita S, Shimoi T, Yonemori K, Tamura K, Fujiwara Y, Hamada A. Visualization of the distribution of nanoparticle-formulated AZD2811 in mouse tumor model using matrix-assisted laser desorption ionization mass spectrometry imaging.Sci Rep. 2020 Sep 23;10(1):15535.
  3. Bun S, Yonemori K, Sunadoi H, Nishigaki R, Noguchi E, Okusaka T, Nishida T, Fujiwara Y. Safety and Evidence of Off-Label Use of Approved Drugs at the National Cancer Center Hospital in Japan. JCO Oncol Pract. 2021 Mar;17(3):e416-e425
  4. Yoshida H, Nishikawa T, Matsumoto K, Mori M, Hirashima Y, Takehara K, Ariyoshi K, Hasegawa K, Yonemori K. Histopathological features of HER2 overexpression in uterine carcinosarcoma: proposal for requirements in HER2 testing for targeted therapy.  Virchows Arch. 2021 Jun;478(6):1161-1171.
  5. Kondo S, Shimizu T, Koyama T, Sato J, Iwasa S, Yonemori K, Fujiwara Y, Shimomura A, Kitano S, Tamura K, Yamamoto N. First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. Cancer Sci. 2021 Apr;112(4):1514-1523.
  6. Hamanishi J, Takeshima N, Katsumata N, Ushijima K, Kimura T, Takeuchi S, Matsumoto K, Ito K, Mandai M, Nakai H, Sakuragi N, Watari H, Takahashi N, Kato H, Hasegawa K, Yonemori K, Mizuno M, Takehara K, Niikura H, Sawasaki T, Nakao S, Saito T, Enomoto T, Nagase S, Suzuki N, Matsumoto T, Kondo E, Sonoda K, Aihara S, Aoki Y, Okamoto A, Takano H, Kobayashi H, Kato H, Terai Y, Takazawa A, Takahashi Y, Namba Y, Aoki D, Fujiwara K, Sugiyama T, Konishi I. Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). J Clin Oncol. 2021 Sep 2:JCO2100334. doi: 10.1200/JCO.21.00334
  7. Shimizu T, Fujiwara Y, Yonemori K, Koyama T, Sato J, Tamura K, Shimomura A, Ikezawa H, Nomoto M, Furuuchi K, Nakajima R, Miura T, Yamamoto N.
    First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-α-Positive Advanced Solid Tumors. Clin Cancer Res. 2021 Jul 15;27(14):3905-3915.
  8. Yonemori K, Shimizu T, Kondo S, Iwasa S, Koyama T, Kitano S, Sato J, Shimomura A, Shibaki R, Suri A, Kase Y, Sumino S, Tamura K, Yamamoto N. The safety, tolerability and pharmacokinetics of niraparib in Japanese patients with solid tumours: results of a phase I dose-escalation study. Jpn J Clin Oncol. 2021 Apr 30;51(5):693-699.
  9. Pujade-Lauraine E, Fujiwara K, Ledermann JA, Oza AM, Kristeleit R, Ray-Coquard IL, Richardson GE, Sessa C, Yonemori K, Banerjee S, Leary A, Tinker AV, Jung KH, Madry R, Park SY, Anderson CK, Zohren F, Stewart RA, Wei C, Dychter SS, Monk BJ. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.  Lancet Oncol. 2021 Jul;22(7):1034-1046.
  10. Doi T, Shitara K, Naito Y, Shimomura A, Fujiwara Y, Yonemori K, Shimizu C, Shimoi T, Kuboki Y, Matsubara N, Kitano A, Jikoh T, Lee C, Fujisaki Y, Ogitani Y, Yver A, Tamura K. Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. Lancet Oncol. 2017 Nov;18(11):1512-1522.

Link

 

Photo